On 18 June 2025, New Zealand made headlines by becoming the latest country to permit psilocybin-assisted therapy, marking a major breakthrough in mental-health care. Associate Health Minister David Seymour announced that, under new regulations, one psychiatrist—Professor Cameron Lacey from the University of Otago—has been authorised to prescribe psilocybin for patients with treatment-resistant depression, provided strict reporting and oversight are in place. As reported by Time, this is the first time such authorisation has been granted in New Zealand outside of clinical trials.
Psilocybin—the psychoactive ingredient in so-called “magic mushrooms”—remains an unapproved medicine, but this limited, supervised rollout represents a careful shift in how the drug can be used. Alongside this decision, the government also announced it will make melatonin more accessible by allowing it to be sold over the counter for sleep disorders, according to Beehive.govt.nz.
Why psilocybin—and why now?
This change is the result of growing evidence that psilocybin can offer relief for people suffering from severe depression, particularly when conventional treatments have failed. Some studies suggest that up to two-thirds of patients with treatment-resistant depression experience lasting improvements after guided psilocybin therapy. Countries like Australia, Canada, Switzerland, and even a few US states such as Oregon and Colorado have already begun legalising or regulating access to this type of treatment. New Zealand’s move places it among a growing list of countries cautiously experimenting with psychedelic-assisted medicine.
Dr Cameron Lacey, the sole psychiatrist currently licensed to prescribe the treatment, previously ran New Zealand’s first clinical trial using psilocybin for depression. He described the therapy as producing “one of the most meaningful impacts” he’s ever seen among his patients. According to the New Zealand Herald, Lacey’s work involves not just administering the compound, but also ensuring that patients receive psychological support before and after their sessions.
The approval remains tightly controlled. Only psychiatrists with prior clinical experience in psilocybin trials can apply, and every session must be documented in detail. The therapeutic process typically includes preparation sessions, the supervised dosing itself, and follow-up integration therapy to help patients process their experiences. The government is also assessing further applications from qualified professionals under similar strict conditions.
What this means for patients and the future of psychedelic treatment
For people who have tried every available option and found no relief, this decision represents a rare glimmer of hope. According to Lacey’s estimates, about two-thirds of his carefully selected patients showed a notable response to psilocybin therapy. That’s a striking contrast to the often modest success rates of standard antidepressants, especially among those with long-term or treatment-resistant symptoms.
But this kind of therapy isn’t cheap. Overseas, psilocybin-assisted treatments can cost thousands of pounds, and they’re often not covered by public healthcare. For now, access in New Zealand will likely be limited to people who can afford the private cost of care. Still, by establishing a legal path forward—even a narrow one—New Zealand has created the potential for future expansion.
The move could also pave the way for more culturally rooted approaches. The country is home to several species of native psilocybin mushrooms, including Psilocybe weraroa, and some Māori-led research groups have shown interest in integrating these natural resources into community-based mental health strategies. A broader regulatory framework that includes indigenous voices could transform New Zealand into a global leader in ethical, culturally sensitive psychedelic medicine.
This change comes amid a wider rethink of how mental illness is treated. The Covid-19 pandemic brought many underlying problems to the surface—rising anxiety, isolation, and the shortcomings of traditional psychiatric medications. Psilocybin isn’t a silver bullet, and researchers remain cautious. There are risks, particularly when used outside clinical settings or without proper support, and some people may experience intense or disorienting psychological effects. But for a subset of patients, the therapy can be life-changing.
A careful beginning, with an eye to the future
New Zealand isn’t opening the floodgates—it’s opening a door. This is a pilot programme in every sense, and it will be watched closely. Data from each session will be collected and used to assess safety, effectiveness, and potential for broader rollout. Other countries are likely to follow its progress with great interest.
Australia’s experience has already shown both the promise and the challenges of implementing such a system. As Drug Science reports, their version of legal psilocybin therapy came with high costs and uneven access. New Zealand will need to learn from those hurdles if it hopes to make the treatment both safe and equitable.
There’s also a long road ahead in changing public perception. The stigma surrounding psychedelics remains strong, and even with scientific backing, many are still wary of substances long associated with counterculture. But the momentum is building, and New Zealand’s decision signals that serious governments are now ready to consider these treatments as part of mainstream care.
For patients who’ve run out of options, and for clinicians like Dr Lacey who believe in the potential of these tools, that’s no small thing. It’s not magic—but for many, it may be the breakthrough they’ve been waiting for.